Lecture abstract:

Micro-clotting has emerged as a critical concern, especially following COVID-19 and related vaccinations. In this lecture, Dr. Jordan Vaughn, CEO and Owner of MedHelp Clinics, addresses this challenge head-on. Drawing from his family’s medical legacy, Dr. Vaughn has made significant strides in identifying and treating micro-clotting, which is distinct from traditional clotting disorders. He presents innovative treatments tailored for spike-protein-related conditions. Dr. Vaughn’s insights emphasize the importance of recognizing and managing microvascular damage, offering hope through advanced medical strategies.

Dr. Vaughn received his Bachelor’s degree in Chemical Engineering from the University of Alabama, his medical degree from the University of Alabama (UAB) School of Medicine, and completed his residency in Internal Medicine at UAB Hospital. After finishing training, Dr. Vaughn brought his knowledge of internal medicine to further expand MedHelp Clinics, which was started by his father, Dr. Michael Vaughn, in 1982.

Focused on caring for patients in all aspects of outpatient medicine — acute and chronic, body and spirit — Medhelp Clinics now has six locations, sees over 190,000 patients a year, and employs 18 physicians and over 200 healthcare workers.

As owner and CEO, Dr. Vaughn pushed the organization since the appearance of SARS-CoV2 to be on the leading edge of properly delivering early outpatient treatment for his patients and the Birmingham community. He is now also incorporating this knowledge into the treatment of those with long COVID (post-acute sequelae SARS-CoV-2 infection or PASC), specifically with regard to the spike protein’s ability to cause endothelial damage and clotting of the microcapillaries.